



(12) Translation of
European patent specification

(11) NO/EP 3366307 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/00 (2006.01)
C07K 16/40 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.11.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.07.28
(86)	European Application Nr.	18158799.9
(86)	European Filing Date	2013.04.05
(87)	The European Application's Publication Date	2018.08.29
(30)	Priority	2012.04.06, US, 201261621461 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(62)	Divided application	EP2833907, 2013.04.05
(73)	Proprietor	Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119, USA University Of Leicester, University Road, Leicester, Leicestershire LE1 7RH, Storbritannia
(72)	Inventor	SCHWAEUBLE, Hans-Wilhelm, University of Cambridge Department of Veterinary Medicine Madingley Road, Cambridge CB3 0ES, Storbritannia DEMOPULOS, Gregory, 4845 Forest Avenue SE, Mercer Island, WA 98040, USA
(74)	Agent or Attorney	Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54)	Title	COMPOSITIONS AND METHODS OF INHIBITING MASP-1 AND/OR MASP-3 FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
(56)	References Cited:	WO-A1-2011/057158, US-A1- 2011 311 549, WO-A2-01/40451 RISITANO A M ET AL: "The human complement receptor type 2/factor H fusion protein TT30, an alternative pathway specific complement inhibitor, prevents hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria by membrane-targeting of factor H activity", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 47, no. 13, 1 August 2010 (2010-08-01), page 2215, XP027120165, ISSN: 0161-5890 [retrieved on 2010-07-03] NIRMAL K BANDA ET AL: "Mechanisms of mannose-binding lectin-associated serine proteases- 1/3 activation of the alternative pathway of complement", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 49, no. 1, 27 August 2011 (2011-08-27), pages 281-289, XP028328168, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2011.08.021 [retrieved on 2011-09-05] S. ZUNDEL ET AL: "Characterization of Recombinant Mannan-Binding Lectin-Associated Serine Protease (MASP)-3 Suggests an Activation Mechanism Different from That of MASP-1 and MASP-2", THE JOURNAL OF IMMUNOLOGY, vol. 172, no. 7, 19 March 2004 (2004-03-19), pages 4342-4350, XP055246991, US ISSN: 0022-1767, DOI: 10.4049/jimmunol.172.7.4342

- ANDREA KOCSIS ET AL: "Selective Inhibition of the Lectin Pathway of Complement with Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway Activation", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 185, 1 January 2010 (2010-01-01), pages 4169-4178, XP007915332, ISSN: 0022-1767, DOI: 10.4049/JIMMUNOL.1001819 [retrieved on 2010-09-03]
- DEGN SØREN E ET AL: "Biological variations of MASP-3 and Map44, two splice products of the MASP1 gene involved in regulation of the complement system", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 361, no. 1, 29 July 2010 (2010-07-29), pages 37-50, XP029816803, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2010.07.006
- WONG N K H ET AL: "ACTIVITIES OF THE MBL-ASSOCIATED SERINE PROTEASES (MASPS) AND THEIR REGULATION BY NATURAL INHIBITORS", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 36, no. 13/14, 1 January 1999 (1999-01-01), pages 853-861, XP001037853, ISSN: 0161-5890, DOI: 10.1016/S0161-5890(99)00106-6
- H. JIANG ET AL: "Complement 1 Inhibitor Is a Regulator of the Alternative Complement Pathway", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 194, no. 11, 3 December 2001 (2001-12-03), pages 1609-1616, XP055246972, US ISSN: 0022-1007, DOI: 10.1084/jem.194.11.1609
- M. FRIDKIS-HARELI ET AL: "Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases", BLOOD, vol. 118, no. 17, 27 October 2011 (2011-10-27), pages 4705-4713, XP055072079, ISSN: 0006-4971, DOI: 10.1182/blood-2011-06-359646

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Farmasøytisk sammensetning omfattende et MASP-2-hemmende monoklonalt antistoff som hemmer aktivering av lektinveikomplement og spesifikt binder seg til en del av SEKV. ID-NR. 5, og et MASP-3 hemmende monoklonalt antistoff som spesifikt binder seg til serinproteasedomenet til humant MASP-3 bestående av aminosyrer 450-711 i SEKV. ID-NR. 8 og hemmer alternativ veikomplementaktivering, og en farmasøytisk akseptabel bærer for anvendelse i behandlingen av paroksysmal nokturn hemoglobinuri (PNH)

2. Sammensetningen ifølge krav 1, hvori det MASP-2-hemmende monoklonale antistoffet velges fra gruppen bestående av et rekombinant antistoff, et kimært og et humanisert eller humant antistoff.

3. Sammensetning ifølge krav 1, hvori sammensetningen formuleres for systemisk avgivelse, slik som for levering subkutan, intra-muskulært, intravenøst, intra-arterielt eller som inhalator.

4. Sammensetningen ifølge krav 1, hvori det MASP-3-hemmende monoklonale antistoffet velges fra gruppen bestående av et rekombinant antistoff, et kimært og et humanisert eller humant antistoff.